Enbrel plant approved
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Full promotion for Amgen/Wyeth's rheumatoid arthritis agent Enbrel will resume with Dec. 23 approval of Rhode Island manufacturing facility. Amgen estimates that approval of plant will double the overall annual supply of the agent; demand has exceeded supply since 200
You may also be interested in...
New China COVID Vaccine Arriving But COVAX Pledge May Need A Booster
China’s first domestically-developed recombinant protein vaccine for COVID-19 moves forward in late-stage trials in two countries.
QUOTED. 9 March 2021. Matthew Trerotola.
Splitting Colfax into separate fabrication technology and specialty medical technology businesses will help both sides of the business grow, CEO Matthew Trerotola said recently.
Catchup Capsule: Key APAC Insights You Need To Read
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This selection of recent insights from our experienced on-the-ground team will help.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: